Page 53 - Read Online

Page 16 of 16 Fetro. Rare Dis Orphan Drugs J 2023;2:7 https://dx.doi.org/10.20517/rdodj.2023.06

J Paediatr Child Health 2012;48:902-6. DOI PubMed
35. European Medicines Agency. Paediatric-use marketing authorisations. https://www.ema.europa.eu/en/human-regulatory/marketing-
authorisation/paediatric-medicines/paediatric-use-marketing-authorisations [Last accessed on 7 Apr 2023].
36. Hachem M, Bonamonte D, Diociaiuti A, Mantuano M, Teruzzi C. Cost-utility analysis of propranolol versus corticosteroids in the
treatment of proliferating infantile hemangioma in Italy. PharmacoEcon Ital Res Artic 2015:17. DOI
37. Jadeja N. The role of IP in strategies for repurposing medicines www.pinsentmasons.com/out-law/analysis/the-role-of-ip-strategies-
repurposing-medicines [Last accessed on 7 Apr 2023].
38. Veldman A, Richter E, Hacker C, Fischer D. The use of off-label medications in newborn infants despite an approved alternative being
available-results of a national survey. Pharmacy (Basel) 2022;10:19. DOI PubMed PMC
39. Ahmed F, Fattani MT, Ali SR, Enam RN. Strengthening the bridge between academic and the industry through the academia-industry
collaboration plan design model. Front Psychol 2022;13:875940. DOI PubMed PMC
40. European Commission. Commission Expert Group on safe and timely access to medicines for patients (“STAMP”) https://
health.ec.europa.eu/medicinal-products/pharmaceutical-committee-veterinary-pharmaceutical-committee-and-expert-groups/
commission-expert-group-safe-and-timely-access-medicines-patients-stamp_en [Last accessed on 7 Apr 2023].
41. European Medicines Agency. Proposal for a framework to support not-for-profit organisations and academia (institutions and
individuals) in drug repurposing https://www.ema.europa.eu/en/documents/other/question-answers-repurposing-pilot-project-proposal-
framework-support-not-profit-organisations_en.pdf [Last accessed on 7 Apr 2023].
42. European Medicines Agency. Building a European innovation platform for the repurposing of medicinal products https://ec.europa.eu/
info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2021-disease-04-02 [Last accessed on 7 Apr
2023].
43. Hechtelt Jonker A, Hivert V, Gabaldo M, et al. Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development
Guidebook. Nat Rev Drug Discov 2020;19:495-6. DOI PubMed
44. Deplanque D, Fetro C, Ferry A, et al. Drug repurposing: from the discovery of a useful pharmacological effect to making the treatment
available to the patient. Therapie 2023;78:10-8. DOI PubMed
45. Innovative health initiative. https://www.ihi.europa.eu/about-ihi [Last accessed on 7 Apr 2023].